#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Sarcoma Extranodal marginal zone B-cell lymphoma (MALT type) Parkinson's disease Eosinophilic oesophagitis Metastatic malignant melanoma Retinal artery occlusion Rhabdoid tumour Juvenile idiopathic arthritis Polymyositis Primary myelofibrosis Malignant melanoma Brain injury Alexander disease Pancreatic carcinoma Rectal cancer More trials…

    Learn about Rare Diseases

    Familial haemophagocytic lymphohistiocytosis Carcinoid syndrome – Treatment Primary hyperoxaluria – Trials in Disease Focal segmental glomerulosclerosis – Life with Disease Splenic marginal zone lymphoma – Life with Disease Nephrotic syndrome – Treatment Inclusion body myositis – Trials in Disease Primary hyperoxaluria – Treatment Mast cell activation syndrome CADASIL More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    [18F]DED Letetresgene Autoleucel Vosilasarm Amiloride Ciclosporin A VANADIUM OXIDE SULFATE Tianeptine Sodium Pentosan Polysulfate Sodium Gadoteric Acid Syn2 Silibinin Tamuzimod Acetate Dexamethasone Acetate Ph. Eur. Dosulepin Hydrochloride LYSERGIDE Avalglucosidase Alfa REGN7544 Elivaldogene Autotemcel LUNRESERTIB Morf-057 More therapies…

    Learn about Your Condition

    Renal impairment Pelizaeus-Merzbacher disease Coronary artery bypass Limb reduction defect Yellow fever Cancer fatigue Tetanus Chondropathy Behavioural addiction Astrocytoma malignant Neonatal respiratory failure Asplenia Pulmonary tuberculosis Diminished ovarian reserve Immune-mediated myositis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

B-cell type acute leukaemia

  • Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Blinatumomab
    • Tocilizumab
    Denmark France Greece Italy The Netherlands Spain +1

  • Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Fludarabine Phosphate
    Germany The Netherlands Spain

  • Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Blinatumomab
    Austria Czechia Denmark Finland France Germany +7

  • A Study to Test the Safety and How AZD4512 Works in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • AZD4512
    Spain

  • Study of LUMC-BOB1-B7-TCR.

    Recruiting

    2 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    • B-cell lymphoma
    • Plasma cell myeloma
    Investigated Drugs:
    • LUMC-BOB1-B7-TCR.1
    The Netherlands

  • Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    • B-cell lymphoma
    • Plasma cell myeloma
    Investigated Drugs:
    • Autologous T-Cells Encoding A Chimeric Antigen Receptor Targeting Human B Cell Maturation Antigen
    • Tisagenlecleucel
    • Rapcabtagene Autoleucel
    Austria Belgium Denmark Finland France Germany +6
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!